Epicatechin - Cardero Therapeutics

Drug Profile

Epicatechin - Cardero Therapeutics

Alternative Names: (+)- Epicatechin

Latest Information Update: 08 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cardero Therapeutics
  • Developer Cardero Therapeutics; Mayo Clinic; University of California, Davis
  • Class Antibacterials
  • Mechanism of Action Mitochondrial protein modulators; Oxidoreductase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Duchenne muscular dystrophy; Friedreich's ataxia
  • Preclinical Heart failure; Mitochondrial disorders

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Nov 2016 Phase-I/II clinical trials in Duchenne muscular dystrophy (In children, In adolescents) in USA (PO) (NCT02964377)
  • 10 Feb 2016 Preclinical trials in Friedreich's ataxia in USA (PO) before February 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top